Learning Objectives
Upon completion of this activity, participants should be able to:
- Compare the adverse event profile of peginterferon/ribavirin alone with the profiles of combination regimens that incorporate newly approved protease inhibitors for the treatment of chronic hepatitis C
- Formulate strategies to prepare patients for potential adverse events that may occur during treatment of chronic hepatitis C
- Apply best practices in the identification and management of adverse effects and quality-of-life issues during HCV therapy
- Provide appropriate care and counsel for patients and their families
Topics covered include:
- Impact of HCV on Health-Related Quality of Life
- Clinical Trial Results With Telaprevir or Boceprevir Plus Peginterferon and Ribavirin
- Drug-Drug Interactions
- Strategies for Preparing Patients for Treatment and the Challenge of Adherence
- Strategies for Management of Adverse Effects and Quality-of-Life Issues